CaspianOliaiMD

Oncology • Los Angeles, CA

Hematologic Oncology

Physician

Join to view full profile

Dr. Oliai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oliai's full profile

Already have an account?

Office
100 Medical Plaza
Suite 550
Los Angeles, CA 90095
Phone+1 310-794-4955

Fax+1 310-794-4955

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2014 - 2016
California Pacific Medical CenterResidency, Radiation Oncology, 2012 - 2016
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 2011 - 2012
Drexel University College of MedicineClass of 2011

Certifications & Licensure

CA State Medical License 2012 - 2026
PA State Medical License 2011 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Start of enrollment: 2024 Aug 03
Withdrawn
Phase 1
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Start of enrollment: 2023 Jan 23
Recruiting
Phase 1, Phase 2
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
Active, not recruiting
Phase 3
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2019 Jul 18
Terminated
Phase 1
Roles: Contact, Principal Investigator
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Start of enrollment: 2020 Mar 04
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2024-12-17
2 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation.
Erik L Lum, Nima Nassiri, Neil Kogut, Caspian Oliai, Anne Raldow
Lancet. 2024-10-05

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual MeetingDecember 12th, 2023